Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

Diabetes and Metabolism

Volumn 40, Issue 6, 2014, Pages S4-S11

  Scheen, A J ^a   Paquot, N ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; Energy balance; Glucotoxicity; Insulin secretion; Insulin sensitivity; Type 2 diabetes

Indexed keywords

AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL; ANTAGONISTS AND INHIBITORS; CALORIC INTAKE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DRUG EFFECTS; ENERGY METABOLISM; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; OVERWEIGHT; PANCREAS ISLET BETA CELL; SECRETION (PROCESS); URINARY EXCRETION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; ENERGY METABOLISM; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MEMBRANE TRANSPORT MODULATORS; OVERWEIGHT; RENAL ELIMINATION; SODIUM-GLUCOSE TRANSPORTER 2; WEIGHT LOSS;

EID: 84918546698     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(14)72689-8     Document Type: Article

References (47)

1. DeFronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009, 26:1185-1192.
3. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008, 29:351-366.
4. Esser N., L'Homme L., De Roover A., Kohnen L., Scheen A.J., Moutschen M., et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013, 56:2487-2497.
5. Scheen A.J., Van Gaal L.F. Combatting the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014, 2:911-922.
6. Rossetti L., Smith D., Shulman G.I., Papachristou D., DeFronzo R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510-1515.
7. Rossetti L., Shulman G.I., Zawalich W., DeFronzo R.A. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987, 80:1037-1044.
8. Abdul-Ghani M.A., Norton L., Defronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32:515-531.
9. Chen L.H., Leung P.S. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 2013, 15:392-402.
10. Scheen AJ. Pharmacodynamics, efficacy and safety of SGLT-2 Inhibitors for the treatment of type 2 diabetes. Drugs 2014 (in press).
11. Balakumar P., Sundram K., Dhanaraj S.A. Dapagliflozin: Glucuretic action and beyond. Pharmacol Res 2014, 82:34-39.
12. List J.F., Whaley J.M. Glucose dynamics and mechanistic implications of SGLT-2 inhibitors in animals and humans. Kidney Int Suppl 2011, (120):S20-S27.
13. Cefalu W.T. Paradoxical insights into whole body metabolic adaptations following SGLT-2 inhibition. J Clin Invest 2014, 124:485-487.
14. Lamos E.M., Younk L.M., Davis S.N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013, 9:763-775.
15. Plosker G.L. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012, 72:2289-2312.
16. Scheen A.J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014, 53:213-225.
17. Poole R.M., Dungo R.T. Ipragliflozin: first global approval. Drugs 2014, 74:611-617.
18. Rossetti L., Giaccari A., DeFronzo R.A. Glucose toxicity. Diabetes Care 1990, 13:610-630.
19. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992, 13:415-431.
20. Macdonald F.R., Peel J.E., Jones H.B., Mayers R.M., Westgate L., Whaley J.M., et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010, 12:1004-1012.
21. Mudaliar S., Henry R.R., Boden G., Smith S., Chalamandaris A.G., Duchesne D., et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014, 16:137-144.
22. Ferrannini E., Muscelli E., Frascerra S., Baldi S., Mari A., Heise T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014, 124:499-508.
23. Kahn B.B., Shulman G.I., DeFronzo R.A., Cushman S.W., Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991, 87:561-570.
24. Han S., Hagan D.L., Taylor J.R., Xin L., Meng W., Biller S.A., et al. Dapagliflozin, a selective SGLT-2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57:1723-1729.
25. Merovci A., Solis-Herrera C., Daniele G., Eldor R., Fiorentino T.V., Tripathy D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014, 124:509-514.
26. Stenlof K., Cefalu W.T., Kim K.A., Alba M., Usiskin K., Tong C., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
27. Polidori D., Sha S., Mudaliar S., Ciaraldi T.P., Ghosh A., Vaccaro N., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013, 36:2154-2161.
28. Polidori D., Mari A., Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014, 57:891-901.
29. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013, 36:2508-2515.
30. Lavalle-Gonzalez F.J., Januszewicz A., Davidson J., Tong C., Qiu R., Canovatchel W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 56:2582-2592..
31. Stein P., Berg J.K., Morrow L., Polidori D., Artis E., Rusch S., et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism 2014, 63:1296-1303.
32. Zambrowicz B., Ogbaa I., Frazier K., Banks P., Turnage A., Freiman J., et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther 2013, 35:1162-1173. e8.
33. Rosenstock J., Cefalu W.T., Lapuerta P., Zambrowicz B., Ogbaa I., Banks P., et al. Greater dose-ranging effects on A1c levels than on glucosuria with LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT-2, in type 2 diabetes on metformin monotherapy. Diabetes Care 2014, Epub 2014/09/13.
34. Barnett A.H. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013, 125:92-100.
35. Bolinder J., Ljunggren O., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97:1020-1031.
36. Bolinder J., Ljunggren O., Johansson L., Wilding J., Langkilde A.M., Sjostrom C.D., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014, 16:159-169.
37. Cefalu W.T., Leiter L.A., Yoon K.H., Arias P., Niskanen L., Xie J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
38. Kim G., Ridderstrale M., Andersen K.R., Zeller C., Woerle H.J., Broedl U. Effect of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes. Diabetologia 2014, 57(Suppl 1):330. Abstract P818.
39. Polidori D., Sanghvi A., Seeley R., Hall K. Predicted temporal changes in energy intake and energy expenditure in subjects with type 2 diabetes treated with canagliflozin. Diabetologia 2014, 57(Suppl 1):331. Abstract P 820.
40. Devenny J.J., Godonis H.E., Harvey S.J., Rooney S., Cullen M.J., Pelleymounter M.A. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012, 20:1645-1652.
41. Perkins B.A., Cherney D.Z., Partridge H., Soleymanlou N., Tschirhart H., Zinman B., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014, 37:1480-1483.
42. Ferrannini G., Hach T.S.C., Ferrannini E. Energy balance following sodium-glucose co-transporter-2 (SGLT-2) inhibition. Diabetologia 2014, 57(Suppl 1):S8. Abstract 3.
43. Bell D.S. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep 2014, 15:152-154.
44. Ueta K., O'Brien T.P., McCoy G.A., Kim K., Healey E.C., Farmer T.D., et al. Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity. Am J Physiol Endocrinol Metab 2014, 306:E1225-E1238.
45. Smulders R.A., Leeflang S., Schliess F., et al. The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus. Diabetologia 2013, 56:S399-S400.
46. Paquot N., Schneiter P., Jequier E., Gaillard R., Lefebvre P.J., Scheen A., et al. Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia 1996, 39:580-586.
47. Bonner C., Kerr-Conte J., Gmyr V., Queniat G., Moerman E., Thevenet J., et al. Glucose transporter SGLT-2 inhibition triggers glucagon secretion in alpha cells. Diabetologia 2014, 57(Suppl 1):S251. Abstract P609.